Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

INTRODUCTION: The aim of this sub-study was to evaluate injection success of patients with rheumatoid arthritis (RA) and their caregivers administering the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF: adalimumab-afzb; Abrilada(®)/Amsparity(®)/Xilbrilada(®)) by prefilled pen (PFP) during the ope...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy M., Bock, Amy E., Zhang, Wuyan, Godfrey, Charles M., Vranic, Ivana, Cronenberger, Carol, Dokoupilová, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127023/
https://www.ncbi.nlm.nih.gov/pubmed/35304684
http://dx.doi.org/10.1007/s40744-022-00439-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127023/
https://www.ncbi.nlm.nih.gov/pubmed/35304684
http://dx.doi.org/10.1007/s40744-022-00439-8

Ejemplares similares